Latest Executive Appointments News

Select Harvests appoints Kristina Hermanson as Managing Director and CEO, aiming to leverage her 25 years of global agribusiness expertise to drive the company’s next growth phase.

Helia Group appoints Mark Senkevics as CEO from December 2026 and Craig Ward as CFO from July 2026, outlining detailed remuneration and transition plans amid ongoing leadership changes.

Australian Clinical Labs appoints Greg Horan as Group CEO effective August 2026, marking a leadership transition after a decade under Melinda McGrath. Horan’s healthcare and operational expertise positions ACL for its next growth phase.

Burgundy Diamond Mines announces a court-approved extension and financing for Arctic Canadian Diamond Company Ltd, alongside appointing Brent Mierau as CFO to steer through ongoing market challenges.

Platina Resources has appointed Dr Paul Polito as Managing Director and CEO, bringing over 30 years of exploration expertise to lead its Western Australian gold projects. His remuneration is heavily tied to operational milestones and share price performance.

Ainsworth Game Technology has confirmed Ryan Comstock as CEO after six months as acting chief, tying his pay to company performance through incentive plans.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.

Celsius Resources is probing an unauthorized directive by an executive to transfer shares in Makilala Mining, leading to the termination of the executive's consulting role amid ongoing ownership conflicts.

Clara Resources has completed acquisition of the Mareeba Gold Project, initiating modern exploration and refocusing its portfolio on Queensland gold assets while securing fresh capital and leadership changes.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

NeuroScientific Biopharmaceuticals reported positive clinical responses in its StemSmart™ Special Access Program for fistulising Crohn’s disease and has initiated manufacturing technology transfer to support Phase 2 trials planned for late 2026.

Unico Silver has reported a 143% surge in its Joaquin project's mineral resource to 167 million ounces silver equivalent, reinforcing its status as a major silver developer. The company also progressed key pre-feasibility studies and expanded its investor reach with a US OTCQB listing.